LTR Pharma Adds Renowned Urologist to Boost SPONTAN and ROXUS Development
LTR Pharma has appointed Associate Professor Darren Katz, a leading urologist and erectile dysfunction expert, to its Scientific Advisory Board, aiming to fast-track the development and commercialization of its innovative nasal spray treatments SPONTAN and ROXUS.
- Associate Professor Darren Katz joins LTR Pharma's Scientific Advisory Board
- A/Prof. Katz brings extensive clinical and international expertise in men's health
- Focus on advancing intranasal ED treatments SPONTAN and ROXUS
- Appointment strengthens LTR Pharma’s clinical capabilities and prescriber networks
- Potential to accelerate commercialisation and global outreach
A Strategic Clinical Appointment
In a move that underscores its commitment to innovation in men's health, LTR Pharma has welcomed Associate Professor Darren Katz to its Scientific Advisory Board. A/Prof. Katz is a distinguished urological surgeon and a recognized authority on erectile dysfunction (ED), bringing a wealth of clinical experience and academic credentials to the company.
His appointment is timely as LTR Pharma pushes forward with its proprietary intranasal drug delivery platform, particularly its lead products SPONTAN and ROXUS. These fast-acting nasal sprays promise a rapid onset of action within 10 minutes, offering a novel alternative to traditional ED treatments that often come with inconvenient dosing or side effects.
Clinical Expertise Meets Commercial Ambition
A/Prof. Katz’s background is impressive: he is a Clinical Associate Professor at the University of Melbourne, Medical Director of Men's Health Melbourne, and the Immediate Past Leader of the Andrology Special Advisory Group to the Urological Society of Australia and New Zealand. His leadership in Australia’s only Prosthetic and Microsurgical Fellowship program further highlights his standing in the field.
His role on the Scientific Advisory Board will be pivotal in guiding LTR Pharma’s research and clinical development strategies. With his extensive network and understanding of prescriber and patient needs, Katz is expected to play a key role in expanding the company’s prescriber base and engaging international opinion leaders, particularly as SPONTAN is currently available in Australia under special access schemes.
Implications for LTR Pharma’s Growth Trajectory
The appointment signals LTR Pharma’s intent to accelerate the commercialisation of its ED treatments and potentially broaden their global footprint. The company’s Executive Chairman, Lee Rodne, emphasized that Katz’s expertise will be instrumental in addressing the significant unmet need for fast-acting, on-demand ED therapies.
Beyond erectile dysfunction, LTR Pharma is also advancing OROFLOW, an intranasal spray targeting oesophageal motility disorders, indicating a broader ambition to leverage its nasal delivery platform across multiple therapeutic areas.
With a respected clinical figure now advising its strategy, LTR Pharma is well-positioned to navigate the complex path from innovative research to market success, potentially reshaping treatment options for men worldwide.
Bottom Line?
With Associate Professor Katz on board, LTR Pharma is poised to fast-track its ED nasal sprays from promising innovation to mainstream treatment.
Questions in the middle?
- How will A/Prof. Katz’s involvement influence regulatory approvals and clinical trial progress?
- What are the timelines for expanding SPONTAN and ROXUS beyond Australia?
- Could LTR Pharma’s intranasal platform disrupt other therapeutic areas beyond ED?
